Results 31 to 40 of about 283,064 (357)
Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours
BMC Cancer, 2019 Background Neuroblastoma (NB) is a paediatric tumour of the sympathetic nervous system. Half of all cases are defined high-risk with an overall survival less than 40% at 5 years from diagnosis.
P. Fusco +13 more
doaj +1 more source
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines [PDF]
, 2017 Neuroblastoma cell lines are an important and cost-effective model used to study oncogenic drivers of the disease. While many of these cell lines have been previously characterized with SNP, methylation, and/or mRNA expression microarrays, there has not ...
Adams, Rebecca N. +9 more
core +2 more sources
RTEL1 gene polymorphisms and neuroblastoma risk in Chinese children
BMC Cancer, 2023 Background Neuroblastoma, a neuroendocrine tumor originating from the sympathetic ganglia, is one of the most common malignancies in childhood. RTEL1 is critical in many fundamental cellular processes, such as DNA replication, DNA damage repair, genomic ...
Ting Zhang +5 more
doaj +1 more source
Japanese Journal of Clinical Oncology, 2018 Neuroblastoma is one of the most common solid tumors in children and has a diverse clinical behavior that largely depends on the tumor biology. Neuroblastoma exhibits unique features, such as early age of onset, high frequency of metastatic disease at diagnosis in patients over 1 year of age and the tendency for spontaneous regression of tumors in ...
Akira, Nakagawara +5 more
openaire +2 more sources
Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]
, 2017 Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht +6 more
core +3 more sources
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.
PLoS ONE, 2021 Investigation of the mechanisms responsible for aggressive neuroblastoma and its poor prognosis is critical to identify novel therapeutic targets and improve survival.
Laura V Bownes +11 more
doaj +1 more source
Pyroptosis-Related Gene Signature Predicts the Prognosis and Immune Infiltration in Neuroblastoma
Frontiers in Genetics, 2022 Neuroblastoma is the most common pediatric extracranial solid tumor. The 5-year survival rate for high-risk neuroblastoma is less than 50%, despite multimodal treatment.
Wanrong Li, Xin Li, Yuren Xia, Jian Wang
doaj +1 more source
Anesthetic management of an infant with giant abdominal neuroblastoma
Brazilian Journal of Anesthesiology, 2017 Neuroblastoma is the most common, non-central nervous system tumor of childhood. It has the potential to synthesize catecholamines. However, the presences of hypertension are uncommon.
Manuel Ángel Gómez-Ríos +2 more
doaj +1 more source
Polyphenon E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells [PDF]
, 2013 This is the author's accepted manuscript. The final published article is available from the link below. Note: In this manuscript as well as in the original published version of this article the word "Polyphenon" was incorrectly spelled in the title as ...
Adrian J. Thrasher +14 more
core +2 more sources
BMC Cancer, 2009 Background Neuroblastoma is a pediatric tumor of neural crest cells that is clinically characterized by its variable evolution, from spontaneous regression to malignancy.
Gingras Denis +5 more
doaj +1 more source